Healthcare - Biotechnology - NASDAQ - US
$ 235.56
-8.67 %
$ 30.4 B
Market Cap
-92.38
P/E
INCOME STATEMENT
1.83 B
REVENUE
-282 M
OPERATING INCOME
-440 M
NET INCOME
EFFICIENCY
Earnings Waterfall
Alnylam Pharmaceuticals, Inc.
| Revenue | 1.83 B |
| Cost Of Revenue | 310 M |
| Gross Profit | 1.52 B |
| Operating Expenses | 1.8 B |
| Operating Income | -282 M |
| Other Expenses | 158 M |
| Net Income | -440 M |
Income Statement
Millions
| Dec-2023 | Dec-2022 | Dec-2021 | Dec-2020 | Dec-2019 | Dec-2018 | Dec-2017 | Dec-2016 | Dec-2015 | Dec-2014 | Dec-2013 | Dec-2012 | Dec-2011 | Dec-2010 | Dec-2009 | Dec-2008 | Dec-2007 | Dec-2006 | Dec-2005 | Dec-2004 | Dec-2003 | Dec-2002 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| REVENUE | ||||||||||||||||||||||
| Revenue | 1 828.3 | 1 037.4 | 844.3 | 492.9 | 219.8 | 74.9 | 89.9 | 47.2 | 41.1 | 50.6 | 47.2 | 66.7 | 82.8 | 100.0 | 100.5 | 96.2 | 50.9 | 26.9 | 5.7 | 4.3 | 0.2 | 0 |
| GROSS PROFIT | ||||||||||||||||||||||
| Cost Of Revenue | 310.4 | 168.8 | 140.1 | 78.1 | 25.1 | 1.8 | 13.4 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Gross Profit | 1 517.9 | 868.6 | 704.1 | 414.8 | 194.7 | 73.1 | 76.5 | 47.2 | 41.1 | 50.6 | 47.2 | 66.7 | 82.8 | 100.0 | 100.5 | 96.2 | 50.9 | 26.9 | 5.7 | 4.3 | 0.2 | 0 |
| OPERATING INCOME | ||||||||||||||||||||||
| Operating Expenses | 1 800.1 | 1 653.7 | 1 412.8 | 1 243.2 | 1 134.1 | 887.8 | 590.0 | 471.7 | 337.1 | 234.8 | 140.1 | 131.2 | 137.6 | 144.1 | 148.6 | 124.0 | 144.1 | 66.4 | 49.2 | 36.5 | 20.6 | 4.2 |
| Selling, General and Administrative Expenses | 795.6 | 770.7 | 620.6 | 588.4 | 479.0 | 382.4 | 199.4 | 89.4 | 60.6 | 44.5 | 27.2 | 44.6 | 38.3 | 37.7 | 39.9 | 27.1 | 23.4 | 16.6 | 13.9 | 11.9 | 7.5 | 0.9 |
| Research and Development Expenses | 1 004.4 | 883.0 | 792.2 | 654.8 | 655.1 | 505.4 | 390.6 | 382.4 | 276.5 | 190.2 | 113.0 | 86.6 | 99.3 | 106.4 | 108.7 | 96.9 | 120.7 | 49.8 | 35.3 | 24.6 | 13.1 | 3.3 |
| Operating Income | (282.2) | (785.1) | (708.7) | (828.4) | (939.4) | (814.7) | (500.1) | (424.6) | (296.0) | (405.0) | (92.9) | (129.5) | (54.8) | (44.1) | (48.1) | (27.8) | (93.2) | (39.5) | (43.5) | (32.3) | (25.1) | (4.2) |
| PRE-TAX INCOME | ||||||||||||||||||||||
| Interest Income Expense | 121.2 | 156.0 | 143.0 | 84.5 | 0 | 29.3 | 12.2 | 8.3 | 5.9 | 2.6 | 1.1 | 1.0 | 1.2 | 2.3 | 5.4 | 0.9 | 1.1 | (1.0) | (1.0) | (0.7) | 0 | 0 |
| Total Other Income | (151.3) | (341.9) | (143.5) | (27.2) | 54.2 | 54.0 | 9.2 | 14.5 | 5.9 | 4.4 | 1.0 | 12.9 | (2.8) | 1.1 | 1.1 | 2.3 | 13.0 | 4.9 | 0.6 | (0.4) | (4.6) | 0 |
| Pre-Tax Income | (433.5) | (1 127.0) | (852.1) | (855.6) | (885.3) | (760.7) | (490.9) | (410.1) | (290.1) | (400.6) | (91.9) | (116.6) | (57.6) | (43.0) | (47.0) | (25.5) | (80.2) | (34.6) | (42.9) | (35.4) | (29.7) | 0 |
| NET INCOME | ||||||||||||||||||||||
| Tax Provision | 6.7 | 4.2 | 0.7 | 2.7 | 0.9 | 0.8 | (25.6) | (23.4) | (24.9) | (40.2) | (2.7) | (10.6) | (5.8) | 0.5 | 0.6 | 0.7 | 5.2 | (4.9) | (0.6) | 0.4 | 4.6 | 86 K |
| Net Income | (440.2) | (1 131.2) | (852.8) | (858.3) | (886.1) | (761.5) | (490.9) | (410.1) | (290.1) | (360.4) | (89.2) | (106.0) | (57.6) | (43.5) | (47.6) | (26.2) | (85.5) | (34.6) | (42.9) | (32.7) | (25.0) | (4.1) |
| EPS | 3.52 | 9.3 | 7.2 | 7.46 | 8.11 | 7.57 | 5.42 | 4.79 | 3.45 | 4.85 | 1.45 | 2.11 | 1.36 | 1.04 | 1.14 | 0.64 | 2.21 | 1.09 | 1.96 | 2.75 | 26.6 | 12.5 |